Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial

Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: A phase III, randomized, double-blind, non-inferiority trial

Objectives: To evaluate the immunogenicity and safety of an anti-rabies monoclonal antibody (mAb), ormutivimab, compared with human rabies immunoglobulin (HRIG). Methods: This phase III trial was designed as a randomized, double-blind, non-inferiority clinical trial in patients aged ≥18 years with s...

Celý popis

Podrobná bibliografie
Hlavní autoři: Xiaoqiang Liu, Yufeng Li, Jingyu Li, Jianmei Zhou, Jiangshu Guo, Yi Pu, Ya Jiang, Yaling Zhou, Zhiwei Jiang, Qun Shu, Cha Wang, Jingke Wang, Yu Zhao, Wei Zhao, Hui Wang, Jingshuang Wei, Hancheng Yu, Jian Gao, Xiaona Li
Médium: Článek
Jazyk:English
Vydáno: Elsevier 2023-09-01
Edice:International Journal of Infectious Diseases
Témata:
Rabies
Postexposure prophylaxis
Monoclonal antibody
Rabies passive immune preparation
Rabies immunoglobulin
Rabies vaccine
On-line přístup:http://www.sciencedirect.com/science/article/pii/S1201971223005696

Internet

http://www.sciencedirect.com/science/article/pii/S1201971223005696

Podobné jednotky